Most advanced bispecific antibodies for cancer

30 May 2021 | Sunday | Analysis

A review of the pipeline of experimental bispecific cancer drugs reveals that many bind to the same T cell protein that Blincyto does, called CD3. Blood cancers such as lymphoma, leukemia and multiple myeloma are the most common target, although solid tumors such as lung and prostate cancers are also drawing attention from developers.

A selected list of the most advanced bispecific antibodies for cancer

Drug	Developer	Targets	Lead indication(s)	Phase of study
Blincyto	Amgen	CD19 x CD3	Leukemia	Approved
Rybrevant	J&J	EGFR x cMET	Lung cancer	Approved
mosunetuzumab	Roche	CD20 x CD3	Lymphoma	3
glofitamab	Roche	CD20 x CD3	Lymphoma	3
epcoritamab	AbbVie, Genmab	CD20 x CD3	Lymphoma, leukemia	3
teclistamab	J&J	BCMA x CD3	Multiple myeloma	2
talquetamab	J&J	GPR5CD x CD3	Multiple myeloma	2
flotetuzumab	Macrogenics	CD123 x CD3	Leukemia	2
tebotelimab	Macrogenics	PD1 x LAG3	Solid tumors	2*
elranatamab	Pfizer	BCMA x CD3	Multiple myeloma	2**
odronextamab	Regeneron	CD20 x CD3	Lymphoma	2
REGN5458	Regeneron	BCMA x CD3	Multiple myeloma	2
acapatamab	Amgen	PSMA x CD3	Prostate, lung cancer	1
pavurutamab	Amgen	BCMA x CD3	Multiple myeloma	1
AMG757	Amgen	DLL3 x CD3	Lung cancer	1

*in combination with other drugs **enrollment paused SOURCE: Company disclosures, clinicaltrials.gov

In multiple myeloma, many companies are taking aim at a disease-specific protein called BCMA, following the same approach of the approved drugs Blenrep from GlaxoSmithKline and Abecma from Bristol Myers Squibb. In leukemia and lymphoma, the target protein on the tumor cells is called CD20, to which the aging Roche drug Rituxan also binds.

Most advanced bispecific antibodies for cancer

A selected list of the most advanced bispecific antibodies for cancer

Stay Connected